272 related articles for article (PubMed ID: 33067454)
21. Whole-genome landscapes of major melanoma subtypes.
Hayward NK; Wilmott JS; Waddell N; Johansson PA; Field MA; Nones K; Patch AM; Kakavand H; Alexandrov LB; Burke H; Jakrot V; Kazakoff S; Holmes O; Leonard C; Sabarinathan R; Mularoni L; Wood S; Xu Q; Waddell N; Tembe V; Pupo GM; De Paoli-Iseppi R; Vilain RE; Shang P; Lau LMS; Dagg RA; Schramm SJ; Pritchard A; Dutton-Regester K; Newell F; Fitzgerald A; Shang CA; Grimmond SM; Pickett HA; Yang JY; Stretch JR; Behren A; Kefford RF; Hersey P; Long GV; Cebon J; Shackleton M; Spillane AJ; Saw RPM; López-Bigas N; Pearson JV; Thompson JF; Scolyer RA; Mann GJ
Nature; 2017 May; 545(7653):175-180. PubMed ID: 28467829
[TBL] [Abstract][Full Text] [Related]
22. The genomic landscape of childhood and adolescent melanoma.
Lu C; Zhang J; Nagahawatte P; Easton J; Lee S; Liu Z; Ding L; Wyczalkowski MA; Valentine M; Navid F; Mulder H; Tatevossian RG; Dalton J; Davenport J; Yin Z; Edmonson M; Rusch M; Wu G; Li Y; Parker M; Hedlund E; Shurtleff S; Raimondi S; Bhavin V; Donald Y; Mardis ER; Wilson RK; Evans WE; Ellison DW; Pounds S; Dyer M; Downing JR; Pappo A; Bahrami A
J Invest Dermatol; 2015 Mar; 135(3):816-823. PubMed ID: 25268584
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
24. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
25. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
27. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.
Lázár V; Ecsedi S; Szöllosi AG; Tóth R; Vízkeleti L; Rákosy Z; Bégány A; Adány R; Balázs M
Mod Pathol; 2009 Oct; 22(10):1367-78. PubMed ID: 19633643
[TBL] [Abstract][Full Text] [Related]
28. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.
Rawson RV; Johansson PA; Hayward NK; Waddell N; Patch AM; Lo S; Pearson JV; Thompson JF; Mann GJ; Scolyer RA; Wilmott JS
Lab Invest; 2017 Feb; 97(2):130-145. PubMed ID: 28067894
[TBL] [Abstract][Full Text] [Related]
29. Clonal architectures and driver mutations in metastatic melanomas.
Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
31. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
32. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
33. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
[No Abstract] [Full Text] [Related]
34. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
35. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
36. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.
Wong K; van der Weyden L; Schott CR; Foote A; Constantino-Casas F; Smith S; Dobson JM; Murchison EP; Wu H; Yeh I; Fullen DR; Joseph N; Bastian BC; Patel RM; Martincorena I; Robles-Espinoza CD; Iyer V; Kuijjer ML; Arends MJ; Brenn T; Harms PW; Wood GA; Adams DJ
Nat Commun; 2019 Jan; 10(1):353. PubMed ID: 30664638
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
38. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
[TBL] [Abstract][Full Text] [Related]
39. Molecular Genomic Profiling of Melanocytic Nevi.
Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
